期刊
CURRENT OPINION IN ONCOLOGY
卷 12, 期 6, 页码 588-593出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00001622-200011000-00012
关键词
-
类别
The increased expression of CD30 on some neoplasms versus its limited expression on normal tissue makes it an excellent target for antibody-based therapy. Recent studies have shown that anti-CD30 antibodies may serve as signaling molecules as well as mediators of interactions with the immune system. Unmodified anti-CD30 antibodies as well as anti-CD30-based bispecific antibodies, immunotoxins, and radioimmunoconjugates have been examined in preclinical and clinical studies. The data show that anti-CD30-based therapies are promising new treatment modalities for CD30+ neoplasms. Curr Opin Oncol 2000, 12:588-593 (C) 2000 Lippincott Williams & Wilkins, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据